azosemide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diuretics, furosemide derivatives	278	27589-33-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: azosemide diurapid azosemid	Molecular weight: 370.83 Formula: C12H11ClN6O2S2 CLOGP: 1.36 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 126.65 ALOGS: -3.59 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

azosemide
diurapid
azosemid

Molecular weight: 370.83
Formula: C12H11ClN6O2S2
CLOGP: 1.36
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 126.65
ALOGS: -3.59
ROTB: 5

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	10 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	205.17	24.93	105	3794	75935	50525290
Renal impairment	117.92	24.93	73	3826	75588	50525637
Cardiac failure chronic	83.65	24.93	24	3875	3539	50597686
Anaemia	71.09	24.93	92	3807	252364	50348861
Cerebral infarction	58.52	24.93	30	3869	21574	50579651
Blood pressure decreased	55.86	24.93	41	3858	55868	50545357
Hepatic function abnormal	54.55	24.93	33	3866	32648	50568577
Pulmonary arterial hypertension	54.41	24.93	28	3871	20291	50580934
Cardiac failure acute	53.14	24.93	21	3878	8229	50592996
Right ventricular failure	51.71	24.93	25	3874	15868	50585357
Brain natriuretic peptide increased	49.46	24.93	17	3882	4510	50596715
Platelet count decreased	47.43	24.93	48	3851	100678	50500547
Pulmonary congestion	46.65	24.93	23	3876	15224	50586001
Concomitant disease aggravated	46.59	24.93	19	3880	8072	50593153
Drug ineffective	43.43	24.93	6	3893	819327	49781898
Pleural effusion	42.38	24.93	41	3858	81413	50519812
Pulmonary hypertension	39.10	24.93	27	3872	33390	50567835
Upper respiratory tract inflammation	38.33	24.93	12	3887	2377	50598848
Fatigue	37.89	24.93	5	3894	707596	49893629
Hyperuricaemia	37.61	24.93	14	3885	4666	50596559
Hypernatraemia	33.53	24.93	14	3885	6307	50594918
Iron deficiency anaemia	33.34	24.93	19	3880	16815	50584410
Interstitial lung disease	31.93	24.93	29	3870	53147	50548078
Cardiac failure congestive	30.52	24.93	35	3864	84347	50516878
Hypokalaemia	27.70	24.93	34	3865	87958	50513267
Dehydration	27.33	24.93	45	3854	152404	50448821
Spinal compression fracture	27.00	24.93	15	3884	12641	50588584
Atrial fibrillation	25.30	24.93	35	3864	101710	50499515
Immobilisation syndrome	25.17	24.93	5	3894	151	50601074

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	163.79	25.06	107	3407	79180	29491833
Renal impairment	137.47	25.06	97	3417	81236	29489777
Hepatic function abnormal	68.83	25.06	48	3466	39211	29531802
Cardiac failure chronic	66.42	25.06	26	3488	6441	29564572
Altered state of consciousness	59.16	25.06	34	3480	19855	29551158
Cerebral infarction	54.87	25.06	35	3479	24640	29546373
Concomitant disease aggravated	54.61	25.06	21	3493	4957	29566056
Blood pressure decreased	37.81	25.06	36	3478	45441	29525572
Interstitial lung disease	37.55	25.06	40	3474	57678	29513335
Dehydration	35.59	25.06	55	3459	114693	29456320
Pneumonia aspiration	32.29	25.06	30	3484	36707	29534306
Cardiac failure acute	30.79	25.06	17	3497	9175	29561838
Right ventricular failure	30.36	25.06	16	3498	7874	29563139
Brain natriuretic peptide increased	29.81	25.06	13	3501	4217	29566796
Hyperkalaemia	27.29	25.06	35	3479	61357	29509656
Hypernatraemia	25.68	25.06	14	3500	7372	29563641

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	317.99	24.32	197	7503	132176	64358856
Renal impairment	231.68	24.32	163	7537	134854	64356178
Cardiac failure chronic	127.82	24.32	46	7654	8995	64482037
Hepatic function abnormal	115.51	24.32	80	7620	64233	64426799
Cerebral infarction	105.59	24.32	64	7636	40980	64450052
Concomitant disease aggravated	96.21	24.32	40	7660	11502	64479530
Blood pressure decreased	74.73	24.32	70	7630	86129	64404903
Anaemia	74.62	24.32	149	7551	378531	64112501
Cardiac failure acute	73.90	24.32	37	7663	16307	64474725
Right ventricular failure	72.56	24.32	40	7660	21431	64469601
Altered state of consciousness	72.38	24.32	49	7651	37853	64453179
Brain natriuretic peptide increased	72.31	24.32	29	7671	7604	64483428
Interstitial lung disease	65.52	24.32	69	7631	97663	64393369
Pulmonary arterial hypertension	61.23	24.32	38	7662	25329	64465703
Platelet count decreased	56.75	24.32	84	7616	167627	64323405
Hypernatraemia	56.30	24.32	28	7672	12161	64478871
Dehydration	56.05	24.32	96	7604	216667	64274365
Fatigue	55.74	24.32	11	7689	748719	63742313
Pleural effusion	55.74	24.32	72	7628	126487	64364545
Hyperuricaemia	54.87	24.32	26	7674	10165	64480867
Drug ineffective	51.83	24.32	18	7682	840229	63650803
Pneumonia aspiration	45.42	24.32	45	7655	59226	64431806
Pulmonary hypertension	45.18	24.32	39	7661	43100	64447932
Pulmonary congestion	43.51	24.32	30	7670	23850	64467182
Iron deficiency anaemia	41.06	24.32	28	7672	21861	64469171
Upper respiratory tract inflammation	38.01	24.32	15	7685	3767	64487265
Hyperkalaemia	36.11	24.32	52	7648	101077	64389955
Haemorrhage subcutaneous	35.95	24.32	15	7685	4346	64486686
Subdural haematoma	34.85	24.32	28	7672	28026	64463006
Cardiac failure congestive	33.91	24.32	58	7642	130522	64360510
Atrial fibrillation	33.16	24.32	67	7633	171022	64320010
Decreased appetite	32.52	24.32	90	7610	281199	64209833
Pneumonia bacterial	32.47	24.32	21	7679	15014	64476018
Pemphigoid	30.18	24.32	19	7681	12967	64478065
Pneumonia	29.99	24.32	139	7561	559437	63931595
Pulmonary alveolar haemorrhage	29.78	24.32	17	7683	9721	64481311
Embolic stroke	29.76	24.32	15	7685	6696	64484336
Cardiothoracic ratio increased	28.19	24.32	5	7695	50	64490982
Pain	27.55	24.32	16	7684	553495	63937537
Disseminated intravascular coagulation	27.48	24.32	26	7674	32322	64458710
Transfusion	26.79	24.32	20	7680	17974	64473058
Liver disorder	26.07	24.32	32	7668	53319	64437713
Urine output decreased	26.06	24.32	19	7681	16473	64474559
Atrial tachycardia	25.22	24.32	11	7689	3548	64487484
Embolic cerebral infarction	24.88	24.32	8	7692	1111	64489921

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D004232	Diuretics
MeSH PA	D045283	Natriuretic Agents
CHEBI has role	CHEBI:77608	loop diuretics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Congestive heart failure	indication	42343007	DOID:6000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.68	acidic
pKa2	10.12	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01323	KEGG_DRUG
18651	RXNORM
C0052820	UMLSCUI
CHEBI:31248	CHEBI
CHEMBL1097235	ChEMBL_ID
DB08961	DRUGBANK_ID
C018222	MESH_SUPPLEMENTAL_RECORD_UI
2273	PUBCHEM_CID
3954	INN_ID
MR40VT1L8Z	UNII
007033	NDDF

Pharmaceutical products:

None